165 related articles for article (PubMed ID: 25682075)
1. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
Erin N; Nizam E; Tanrıöver G; Köksoy S
Breast Cancer Res Treat; 2015 Feb; 150(1):57-69. PubMed ID: 25682075
[TBL] [Abstract][Full Text] [Related]
2. Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.
Erin N; Tavşan E; Akdeniz Ö; Isca VMS; Rijo P
Cytokine; 2021 Jun; 142():155498. PubMed ID: 33773907
[TBL] [Abstract][Full Text] [Related]
3. Differential characteristics of heart, liver, and brain metastatic subsets of murine breast carcinoma.
Erin N; Kale S; Tanrıöver G; Köksoy S; Duymuş O; Korcum AF
Breast Cancer Res Treat; 2013 Jun; 139(3):677-89. PubMed ID: 23760857
[TBL] [Abstract][Full Text] [Related]
4. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
5. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
Kale Ş; Korcum AF; Dündar E; Erin N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
[TBL] [Abstract][Full Text] [Related]
6. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells.
Jia D; Li L; Andrew S; Allan D; Li X; Lee J; Ji G; Yao Z; Gadde S; Figeys D; Wang L
Cell Death Dis; 2017 Jul; 8(7):e2932. PubMed ID: 28703802
[TBL] [Abstract][Full Text] [Related]
7. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade.
Yung MM; Tang HW; Cai PC; Leung TH; Ngu SF; Chan KK; Xu D; Yang H; Ngan HY; Chan DW
Theranostics; 2018; 8(5):1270-1285. PubMed ID: 29507619
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
9. Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury.
Qin CC; Liu YN; Hu Y; Yang Y; Chen Z
World J Gastroenterol; 2017 May; 23(17):3043-3052. PubMed ID: 28533661
[TBL] [Abstract][Full Text] [Related]
10. Metastatic breast carcinoma induces vascular endothelial dysfunction in Balb-c mice: Role of the tumor necrosis factor-α and NADPH oxidase.
Dalaklioglu S; Tasatargil A; Kale S; Tanriover G; Dilmac S; Erin N
Vascul Pharmacol; 2013; 59(3-4):103-11. PubMed ID: 23933568
[TBL] [Abstract][Full Text] [Related]
11. The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.
Acker G; Zollfrank J; Jelgersma C; Nieminen-Kelhä M; Kremenetskaia I; Mueller S; Ghori A; Vajkoczy P; Brandenburg S
Eur J Cancer; 2020 Feb; 126():106-115. PubMed ID: 31927212
[TBL] [Abstract][Full Text] [Related]
12. Cross-desensitization among CXCR1, CXCR2, and CCR5: role of protein kinase C-epsilon.
Nasser MW; Marjoram RJ; Brown SL; Richardson RM
J Immunol; 2005 Jun; 174(11):6927-33. PubMed ID: 15905535
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic augmentation of the macrophage inflammatory protein 2/C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain.
Kiguchi N; Kobayashi Y; Maeda T; Fukazawa Y; Tohya K; Kimura M; Kishioka S
J Pharmacol Exp Ther; 2012 Mar; 340(3):577-87. PubMed ID: 22135382
[TBL] [Abstract][Full Text] [Related]
14. Altered gene expression in breast cancer liver metastases.
Erin N; Wang N; Xin P; Bui V; Weisz J; Barkan GA; Zhao W; Shearer D; Clawson GA
Int J Cancer; 2009 Apr; 124(7):1503-16. PubMed ID: 19117052
[TBL] [Abstract][Full Text] [Related]
15. CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells.
Lepsenyi M; Algethami N; Al-Haidari AA; Algaber A; Syk I; Rahman M; Thorlacius H
Clin Exp Metastasis; 2021 Aug; 38(4):401-410. PubMed ID: 34115261
[TBL] [Abstract][Full Text] [Related]
16. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
[TBL] [Abstract][Full Text] [Related]
17. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells.
Zhu YM; Webster SJ; Flower D; Woll PJ
Br J Cancer; 2004 Nov; 91(11):1970-6. PubMed ID: 15545974
[TBL] [Abstract][Full Text] [Related]
19. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.
Wislez M; Fujimoto N; Izzo JG; Hanna AE; Cody DD; Langley RR; Tang H; Burdick MD; Sato M; Minna JD; Mao L; Wistuba I; Strieter RM; Kurie JM
Cancer Res; 2006 Apr; 66(8):4198-207. PubMed ID: 16618742
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice.
Kuboki S; Shin T; Huber N; Eismann T; Galloway E; Schuster R; Blanchard J; Edwards MJ; Lentsch AB
Hepatology; 2008 Oct; 48(4):1213-23. PubMed ID: 18688883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
